Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
NMR Biomed ; 29(11): 1577-1589, 2016 11.
Article in English | MEDLINE | ID: mdl-27717037

ABSTRACT

Glioma models have provided important insights into human brain cancers. Among the investigative tools, MRI has allowed their characterization and diagnosis. In this study, we investigated whether diffusion MRI might be a useful technique for early detection and characterization of slow-growing and diffuse infiltrative gliomas, such as the proposed new models, LN-2669GS and LN-2540GS glioma sphere xenografts. Tumours grown in these models are not visible in conventional T2 -weighted or contrast-enhanced T1 -weighted MRI at 14.1 T. Diffusion-weighted imaging and diffusion tensor imaging protocols were optimized for contrast by exploring long diffusion times sensitive for probing the microstructural alterations induced in the normal brain by the slow infiltration of glioma sphere cells. Compared with T2 -weighted images, tumours were properly identified in their early stage of growth using diffusion MRI, and confirmed by localized proton MR spectroscopy as well as immunohistochemistry. The first evidence of tumour presence was revealed for both glioma sphere xenograft models three months after tumour implantation, while no necrosis, oedema or haemorrhage were detected either by MRI or by histology. Moreover, different values of diffusion indices, such as mean diffusivity and fractional anisotropy, were obtained in tumours grown from LN-2669GS and LN-2540GS glioma sphere lines. These observations highlighted diverse tumour microstructures for both xenograft models, which were reflected in histology. This study demonstrates the ability of diffusion MRI techniques to identify and investigate early stages of slow-growing, invasive tumours in the mouse brain, thus providing a potential imaging biomarker for early detection of tumours in humans.


Subject(s)
Brain Neoplasms/diagnostic imaging , Brain Neoplasms/pathology , Diffusion Magnetic Resonance Imaging/methods , Early Detection of Cancer/methods , Glioma/diagnostic imaging , Glioma/pathology , Algorithms , Animals , Cell Line, Tumor , Female , Humans , Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Mice , Mice, Nude , Neoplasm Invasiveness , Reproducibility of Results , Sensitivity and Specificity , Spheroids, Cellular/pathology
2.
Appl Radiat Isot ; 67(7-8 Suppl): S34-6, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19375337

ABSTRACT

One of the main limitations for BNCT effectiveness is the insufficient intake of (10)B nuclei within tumour cells. This work was aimed at investigating the use of L-DOPA as enhancer for boronophenylalanine (BPA) uptake in the C6 glioma model. The investigation was first performed in vitro, and then extended in vivo to the animal model. BPA accumulation in C6 glioma cells was assessed, using radiowave dielectric spectroscopy (RDS), with and without L-DOPA preloading. C6 glioma cells were also implanted in the brain of 25 rats, randomly assigned to two experimental branches: (1) intra-carotid BPA infusion; (2) intra-carotid BPA infusion after pre-treatment with L-DOPA, administrated 24 h before BPA infusion. All animals were sacrificed, and assessment of BPA concentrations in tumour tissue, normal brain, and blood samples was performed using high performance liquid chromatography (HPLC). L-DOPA preloading induced a massive increase of BPA concentration either in vitro on C6 glioma cells or in vivo in the animal model tumour. Moreover, no significant difference was found in the normal brain and blood samples between the two animal groups. This study suggests the potential use of L-DOPA as enhancer for BPA accumulation in malignant gliomas eligible for BNCT.


Subject(s)
Boron Compounds/administration & dosage , Boron Compounds/pharmacokinetics , Brain Neoplasms/metabolism , Glioma/metabolism , Levodopa/administration & dosage , Phenylalanine/analogs & derivatives , Radiation-Sensitizing Agents/administration & dosage , Radiation-Sensitizing Agents/pharmacokinetics , Animals , Boron Compounds/therapeutic use , Boron Neutron Capture Therapy , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Cell Line, Tumor , Glioma/pathology , Glioma/radiotherapy , In Vitro Techniques , Magnetic Resonance Imaging , Male , Phenylalanine/administration & dosage , Phenylalanine/pharmacokinetics , Phenylalanine/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Rats , Rats, Wistar
3.
Appl Radiat Isot ; 67(7-8 Suppl): S365-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19375924

ABSTRACT

The aim of this study was to evaluate in vivo the boron biodistribution and pharmacokinetics of 4-borono-2-fluorophenylalanine ((19)F-BPA) using (19)F MR Imaging ((19)F MRI) and Spectroscopy ((19)F MRS). The correlation between the results obtained by both techniques, (19)F MRI on rat brain and (19)F MRS on blood samples, showed the maximum (19)F-BPA uptake in C6 glioma model at 2.5h after infusion determining the optimal irradiation time. Moreover, the effect of L-DOPA as potential enhancer of (19)F-BPA tumour intake was assessed using (19)F MRI.


Subject(s)
Boron Compounds/pharmacokinetics , Boron Neutron Capture Therapy/methods , Fluorine/analysis , Fluorine/pharmacokinetics , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy/methods , Phenylalanine/analogs & derivatives , Animals , Boron Compounds/therapeutic use , Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Cell Line, Tumor , Glioma/metabolism , Glioma/radiotherapy , In Vitro Techniques , Male , Phenylalanine/pharmacokinetics , Phenylalanine/therapeutic use , Radiation-Sensitizing Agents/pharmacokinetics , Radiation-Sensitizing Agents/therapeutic use , Rats , Rats, Wistar , Tissue Distribution
4.
Abdom Imaging ; 25(1): 45-7, 2000.
Article in English | MEDLINE | ID: mdl-10652920

ABSTRACT

Differentiating bowel intussusception occurring in adults from other bowel diseases represents a diagnostic problem because this condition is not a common finding. Contrast radiography, computed tomography, magnetic resonance imaging, and abdominal ultrasonography are imaging techniques suitable for this diagnosis. Sonography is easy to perform, reproducible, and less invasive than the other techniques. The aim of the present study was to evaluate the diagnostic utility of abdominal sonography in four patients affected by bowel intussusception and to assess the advantages offered by this method.


Subject(s)
Ileocecal Valve/diagnostic imaging , Intussusception/diagnostic imaging , Jejunal Diseases/diagnostic imaging , Adult , Diagnosis, Differential , Female , Humans , Ileal Diseases/diagnostic imaging , Male , Middle Aged , Reproducibility of Results , Ultrasonography
5.
J Hepatol ; 25(2): 212-7, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8878784

ABSTRACT

BACKGROUND: The clinical outcome of hepatitis virus infections is though to depend on the complex interplay between the host immune response profile and virus factors. 90K/MAC-2 BP is a novel member of the Scavenger Receptor Cysteine Rich protein superfamily that functions as a molecular alarm signal for the cellular immune system against both cancer cells and virus infections. METHODS: To assess the significance and the potential clinical usefulness of testing for serum levels of 90K/MAC-2 BP in chronic viral hepatitis patients we studied 115 consecutive patients with chronic HCV hepatitis, 28 HBsAg chronic hepatitis patients, 12 asymptomatic HCV carriers and 11 asymptomatic HBV carriers. 103 out of the 115 HCV patients have been treated with recombinant alpha 2a-interferon at the dose of 3 Mega Units (MU) t.i.w. for 6 months followed by 1.5 MU t.i.w. for 6 months, and have been followed up for a further 12 months. Serum levels of 90K/MAC-2 BP were measured by an immunoradiometric assay based on the specific SP-2 monoclonal antibody. RESULTS AND CONCLUSIONS: Serum 90K/MAC-2 BP levels are increased in chronic viral hepatitis patients, being significantly higher in HCV than in HBV patients. In chronic HCV hepatitis, serum 90K/MAC-2 BP levels are related to both the degree of disease severity and duration of infection. Moreover, elevated 90K/MAC-2 BP serum levels are an independent predictor of failure to respond to alpha-interferon treatment in a cohort of community-acquired chronic hepatitis C patients.


Subject(s)
Carrier Proteins/blood , Glycoproteins/blood , Hepatitis C/therapy , Interferon-alpha/therapeutic use , Lipoproteins/blood , Neoplasm Proteins/blood , Adult , Aged , Antigens, Neoplasm , Biomarkers, Tumor , Carrier State/blood , Chronic Disease , Cohort Studies , Female , Forecasting , Hepatitis B/blood , Hepatitis B/physiopathology , Hepatitis B/therapy , Hepatitis C/blood , Hepatitis C/physiopathology , Humans , Male , Middle Aged , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...